Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
IMPAVIDO
(miltefosine)Orphan drugstandardKnight Therapeutics (USA)
Antileishmanial [EPC]
12.1 Mechanism of Action Miltefosine is an anti-leishmanial agent [see Clinical Pharmacology ( 12.4 )] .
Lauren M. Pachman, MD, MD
Northwestern University Feinberg School of Medicine
📍 CHICAGO, IL
Robert Micheletti, MD, MD
University of Pennsylvania
📍 PHILADELPHIA, PA
Peter Grayson, MD, MSc, MD
The National Institute of Arthritis and Musculoskeletal and Skin Diseases
📍 BOSTON, MA
Cord Sunderkoetter
Department of Dermatology, Univ Hospital of Muenster